NCT03795441CompletedPhase 1
Open Label, Single Arm Phase 1 Study to Evaluate the Shedding, Biodistribution, Safety and Immunogenicity of Ad26.RSV.preF Vaccine in Adults
Janssen Vaccines & Prevention B.V.2 sites in 1 country24 target enrollmentStarted: January 7, 2019Last updated:
Conditions
Interventions
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Enrollment
- 24
- Locations
- 2
- Primary Endpoint
- Percentage of Participants with Presence of Ad26.RSV.preF (shedding) as Assessed by qPCR
Study Overview
Brief Summary
The purpose of this study is to assess the shedding and kinetics of the Adenovirus Serotype 26 Based Respiratory Syncytial Virus Pre-fusion F Protein (Ad26.RSV.preF) vaccine after one intramuscular injection of Ad26.RSV.preF in adults.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Prevention
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •In the investigator's clinical judgment, participant must be in good or stable health. Participants may have underlying illnesses such as hypertension, Type 2 diabetes mellitus, hyperlipoproteinemia, or hypothyroidism, as long as their symptoms and signs are medically controlled. If they are on medication for a condition, the medication dose must have been stable for at least 12 weeks preceding vaccination and expected to remain stable for the duration of the study. Participants will be included on the basis of physical examination, medical history, vital signs measurement and 12-lead electrocardiogram (ECG; for participants greater than [>] 65 years of age only) performed at screening
- •Contraceptive use by women should be consistent with local regulations regarding the use of contraceptive methods for participants in clinical studies
- •All women of childbearing potential must have a negative highly sensitive serum beta-human chorionic gonadotropin (beta-hCG) pregnancy test at screening and a negative urine beta-hCG pregnancy test immediately prior to study vaccine administration
- •From the time of vaccination through 3 months after vaccination, participant agrees not to donate blood
- •Participant must be willing to provide verifiable identification, have means to be contacted and to contact the investigator during the study
Exclusion Criteria
- •Participant has a serious chronic disorder, including severe chronic obstructive pulmonary disease or clinically significant congestive heart failure, requirement for supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, Alzheimer's disease, or has any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant (eg, compromise well-being) or that could prevent, limit, or confound the protocol-specified assessments
- •Per medical history, participant has chronic active hepatitis B or hepatitis C infection
- •Participant has received an investigational drug or used an invasive investigational medical device within 30 days or received an investigational vaccine within 6 months before the planned administration of study vaccine or is currently enrolled or plans to participate in another investigational study during the course of this study
- •Participant has received treatment with immunoglobulin in the 2 months, or blood products in the 4 months before the planned administration of study vaccine or has any plans to receive such treatment during the study
- •Participant has received any RSV vaccine in any previous RSV vaccine study at any time prior to randomization
Arms & Interventions
Ad26.RSV.preF
Experimental
Participants will receive one intramuscular injection of an adenovirus serotype 26- based vaccine encoding for the respiratory syncytial virus pre-fusion F protein (Ad26.RSV.preF) on Day 1.
Intervention: Ad26.RSV.preF (Biological)
Outcomes
Primary Outcomes
Percentage of Participants with Presence of Ad26.RSV.preF (shedding) as Assessed by qPCR
Time Frame: Up to Day 183
Percentage of Participants with presence of Ad26.RSV.preF in the adhesive bandage covering the injection site, the injection site area, nares (mid-turbinate), throat, rectum, urine, semen and blood, will be assessed by Quantitative Polymerase Chain Reaction (qPCR). Percentage of participants with presence of Ad26.RSV.preF (shedding) will be assessed.
Secondary Outcomes
- Number of Participants with Solicited Local and Systemic Adverse Events (AEs) After Vaccination(7 days after vaccination (Day 1 up to Day 7))
- Number of Participants with Unsolicited AEs as a Measure of Safety(Day 1 Up to Day 28)
- Number of Participants with Serious Adverse Events (SAEs)(First vaccination (Day 1) to the end of the study (Day 183))
Investigators
Study Sites (2)
Loading locations...
Similar Trials
Completed
Phase 1
Safety and Efficacy Study of Vaccine Schedule With Ad26.Mos.HIV and MVA-Mosaic in Human Immunodeficiency Virus (HIV)-Infected AdultsHuman Immunodeficiency VirusNCT02919306Janssen Vaccines & Prevention B.V.27
Recruiting
Phase 1
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.Malignant Glioma of BrainMalignant AstrocytomaBrain CancerGlioblastomaAstrocytomaGliomaGlioblastoma MultiformeBrain TumorGBMNCT05686798Henry Ford Health System18
Completed
Phase 1
A Study of Ad26.COV2.S in Healthy Adults (COVID-19)HealthyNCT04894305Janssen Vaccines & Prevention B.V.380
Completed
Phase 1
Dose Escalation Study to Determine the Safety of IFN-Beta Gene Transfer in the Treatment of Grade III & Grade IV GliomasAnaplastic AstrocytomaOligoastrocytoma, MixedGliosarcomaGlioblastoma MultiformeNCT00031083Biogen12
Completed
Phase 1
Phase 1/2 Safety and Efficacy Study of AAV-RPE65 Vector to Treat Leber Congenital AmaurosisLeber Congenital AmaurosisNCT00749957Applied Genetic Technologies Corp12